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Experimentalallergic encephalomyelitis (EAE) is an animal model for inﬂammatory demyeli-
nating autoimmune disease, i.e., multiple sclerosis (MS). In the present study, we
investigated the antineuroinﬂammatory/neuroprotective effects of C16, an αυβ3 integrin-
binding peptide, and recombinant rat ciliary neurotrophic factor (CNTF), a cytokine that
was originally identiﬁed as a survival factor for neurons, in an acute rodent EAE model.
In this model, C16 peptide was injected intravenously every day for 2 weeks, and
CNTF was delivered into the cerebral ventricles with Alzet miniosmotic pumps. Disease
severity was assessed weekly using a scale ranging from 0 to 5. Multiple histological and
molecular biological assays were employed to assess inﬂammation, axonal loss, neuronal
apoptosis, white matter demyelination, and gliosis in the brain and spinal cord of different
groups. Our results showed that the EAE induced rats revealed a signiﬁcant increase in
inﬂammatory cells inﬁltration, while C16 treatment could inhibit the inﬁltration of leukocytes
and macrophages down to 2/3–1/3 of vehicle treated EAE control (P < 0.05). The delayed
onset of disease, reduced clinical score (P < 0.01) in peak stage and more rapid recovery
also were achieved in C16 treated group. Besides impairing inﬂammation, CNTF treatment
also exerted direct neuroprotective effects, decreasing demyelination and axon loss score
(P < 0.05 versus vehicle treated EAE control), and reducing the neuronal death from
40 to 50% to 10 to 20% (P < 0.05). Both treatments suppressed the expression of
cytokine tumor necrosis factor-α and interferon-γ when compared with the vehicle control
(P < 0.05). Combined treatment with C16 and CNTF produced more obvious functional
recovery and neuroprotective effects than individually treatment (P < 0.05). These
results suggested that combination treatment with C16 and CNTF, which target different
neuroprotection pathways, may be an effective therapeutic alternative to traditional
therapy.
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INTRODUCTION
Multiple sclerosis (MS) is a central nervous system (CNS)
autoimmune disease with symptoms that include neurological
impairment and motor deﬁcits (Hou et al., 2012). MS results
from attack of myelin by the immune system, which leads
to axonal and neuronal degeneration (Stanislaus et al., 2004;
Huizinga et al., 2008; Yin et al., 2010). Experimental autoimmune
encephalomyelitis (EAE) is the primary animal model of MS,
characterized by microglial activation and lymphocyte inﬁltra-
tion (Arnon and Aharoni, 2009; Mix et al., 2010; Yin et al., 2012).
Consequent demyelination, axonal injury, and neuronal loss also
underlie the disability and disease progression observed in EAE
(Arnon and Aharoni, 2009).
Abbreviations: ABC, avidin–biotin peroxidase complex; ANOVA, analysis of vari-
ance; BBB, blood-brain barrier; CFA, complete Freud adjuvant; CNS, central
nervous system; CNTF, ciliary neurotrophic factor; EAE, experimental allergic
encephalomyelitis; GFAP, glia ﬁbrillary acidic protein; GPSCH, guinea pig spinal
Current treatment strategies for EAE and MS mainly target
injury sites at the CNS, interfering with both neuroinﬂammation
and neurodegeneration (Arnon and Aharoni, 2009). To migrate
into sites of inﬂammation, leukocytes ﬁrst tether and roll along the
vessel, then adhere and emigrate out of the vasculature (Alon and
Luscinskas, 2004). Leukocyte-endothelium interactions have been
recognized as playing an important role in this leukocyte inﬁltra-
tion process (Weerasinghe et al., 1998; Alon and Luscinskas, 2004).
Additionally, previous studies have shown that integrin alpha V
beta 3 (αυβ3) can modulate leukocyte adhesion to intercellular
adhesion molecule-1 (ICAM-1) and enable leukocytes to migrate
effectively across the endothelium (Weerasinghe et al., 1998).
The synthetic C16 peptide, representing a functional laminin
domain, selectively binds to αυβ3 integrin (Ponce et al., 1999).
cord homogenate; ICAM-1, intercellular adhesion molecule-1; IFN-γ, interferon-γ;
MRI, magnetic resonance imaging; MS, multiple sclerosis; PNS, peripheral nerve
system; TEM, transendothelial migration; TGF-β, transforming growth factor beta;
TNF-α, tumor necrosis factor-α.
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Since αυβ3 has been shown to mediate leukocyte adhesion and
migration, this αυβ3-binding peptide could block αυβ3 and
reduce monocyte transmigration across the endothelial cell layer.
In fact, C16 exerted blocking effects on αυβ3 that were simi-
lar to the effects of blocking antibodies against αυβ3 integrins
in vitro (Han et al., 2010; Fang et al., 2013). Intravenous injec-
tion of C16 has also been shown to reduce the inﬁltration
of leukocytes, extravasation of macrophages, and accumula-
tion of activated microglia in vivo (Han et al., 2010; Fang et al.,
2013). The fact that leukocyte inﬁltration was inhibited with
no effects on systemic leukocyte counts implies that the C16
peptide may be a potential therapeutic agent for MS treatment
(Han et al., 2010).
Ciliary neurotrophic factor (CNTF) was described originally as
a neurocytokine that could promote the survival of neurons and
the differentiation and maturation of oligodendrocytes (Linker
et al., 2002; Stankoff et al., 2002; Kuhlmann et al., 2006). As a mod-
ulator in neuroinﬂammation and a neurotrophic agent, CNTF
has also recently been proposed to be a major protective factor
in the treatment of inﬂammatory demyelinating disease (Linker
et al., 2002; Kuhlmann et al., 2006). Indeed, clinical disabili-
ties in acute EAE are due in part to demyelination and axonal
disruption, which are caused by an early inﬂammatory attack
on white matter (Brück, 2005). Demyelination in the periph-
eral nerve system (PNS) and CNS is an important cause of the
neurological deﬁcits in acute EAE induced by whole spinal cord
homogenates (Pender, 1989). Thus, CNTF may be a useful clinical
agent.
C16 has been shown to reduce inﬂammatory cell inﬁltration
in EAE (Fang et al., 2013). Moreover, since previous studies have
suggested that promoting remyelination appeared to be a crucial
therapeutic challenge of MS, CNTF, as a survival and differen-
tiation factor for neurons and oligodendrocytes, may promote
remyelination and prevent neuronal damage. Combination of dif-
ferent drugs that target different pathways of neuroprotection
may produce more effective therapeutic results; therefore, the
present study was designed to investigate the combined thera-
peutic effects of C16 and CNTF in an acute EAE model induced
in Lewis rats, and in this study, combination of different drugs
that target different pathways of neuroprotection may produce
more effective therapeutic results; therefore, the present study
was designed to investigate the combined therapeutic effects
of C16 and CNTF in an acute EAE model induced in Lewis
rats.
Among a variety of EAE models in rodents, the acute EAE
model induced in Lewis rats is a well-established model of MS,
characterized by a single peak of paralysis after which animals
recover spontaneously (Almolda et al., 2011). The utilization of
thismodel gives us anopportunity to elucidate the induction, peak,
and resolution of the inﬂammation-based immune response of
MS. However, the most obvious shortcoming of this acute model
was not allow us to test the impact of C16 on advanced manifes-
tations of the MS disease, including the long-term occurrence
of extensive axonal damage resulting from sustained demyeli-
nation (Basso et al., 2008; Soulika et al., 2009; Berard et al.,
2010), thus the EAE process were observed within a period of
8 weeks.
MATERIALS AND METHODS
EXPERIMENTAL PROCEDURES
Animals and EAE induction
A total of 69 adult male Lewis rats, weighing 250–300 g, were
obtained from the Laboratory Animal Services Centre of the
Zhejiang University. Of these, ﬁve were used as the normal con-
trol group and the remaining 64 were randomly assigned into
four groups: the vehicle control treated group, C16 [synthe-
sized by Shanghai Science Peptide Biological Technology Co., Ltd,
China; 1 mg/per day, intravenous (IV) injection] treated group,
CNTF [PeproTech Inc., NJ, USA; 10 μg, intrathecal administra-
tion (IT), see details below] treated group, and CNTF + C16
treated group. EAE was induced in both drug- and vehicle-
treated rats with subcutaneously nuchal injection of 0.2 mL a
1:1 mixture of guinea pig spinal cord homogenate (GPSCH)
and complete Freud adjuvant (CFA), containing 0.5 mg of heat
killed Mycobacterium tuberculosis (Difco Laboratories, Detroit,
MI, USA). The rats in the normal control group were injected
with CFA emulsiﬁed 1:1 with 0.9% saline. Immediately thereafter,
and again 48 h later, the rats received an intraperitoneal injection
of 300 ng Pertussis toxin per animal (Sigma-Aldrich, St. Louis,
MO, USA).
Beginning on day 7, the animals were weighed and assessed
for clinical signs of disease on a daily basis. Disease severity was
assessed using a scale ranging from0 to 5: grade 0=no signs, grade
1 = partial loss of tail tonicity, grade 2 = loss of tail tonicity, grade
3= unsteady gait and mild paralysis, grade 4 = hind limb paralysis
and incontinence, and grade 5 = moribund or death (Yin et al.,
2010). The EAE model was generally considered a success when
the score exceeded 2, and scoring of the animals was continued
until the time of sacriﬁce.
All animal procedures used in this study were carried out in
accordance with the National Institute of Health Guide for the
Care and Use of Laboratory Animals.
PREPARATION OF OSMOTIC PUMPS AND DRUG DELIVERY
Ciliary neurotrophic factor and vehicle were delivered contin-
uously via implanted Alzet osmotic minipumps over 2 weeks
(pump model 2002; 0.5 μL/h). All the osmotic minipumps were
implanted immediately after receiving EAE induction (GPSCH
and ﬁrst time Pertussis toxin injection). Before implantation, 48
osmotic minipumps were prepared under sterile conditions and
ﬁlled with PBS (n= 16 for the vehicle-treated group) and CNTF in
saline (n = 16 rats per group for CNTF− and CNTF+C16-treated
groups). Cannula consisting of polyurethane tubing were steril-
ized overnight in 100% ethanol before being attached to the ﬂow
moderator of the pump. The pumps were incubated overnight
at room temperature in sterile saline for priming. The animals
were anesthetized with intraperitoneal injections of 1% Nembu-
tal (40 mg/kg), under an operating microscope, the tabs on the
top of the cannula were attached to the electrode holder of the
stereotaxic apparatus, and the catheters were introduced into the
cerebral ventricle through small holes in the skull, according to
the manufacturer’s instructions for the Alzet brain infusion kit
(The surgical details of placing Alzet brain infusion kit could
be found at http://www.alzet.com/products/brain_infusion_kit/
how_it_works.html). The infusion was started immediately.
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The anchoring screws were set with dental cement, and
the pump was placed in a subcutaneous pocket. The scalp
wound was closed in layers. After the surgery, rats were
placed in temperature- and humidity-controlled chambers
overnight, and penicillin was injected intramuscularly (25,000 UI
per rat).
INTRAVENOUS INJECTION OF C16
C16 peptide was dissolved in distilled water with 0.3% acetic acid.
The peptide solution was sterilized through a 0.22-μm disk ﬁlter
and neutralized with NaOH. This solution was buffered by adding
an equal volume of sterile PBS, and the ﬁnal concentration of
C16 was 2 mg/mL. The vehicle solution was prepared in the same
manner (0.3% acetic acid neutralized to pH7.4 with NaOH, then
buffered by adding an equal volume of sterile phosphate-buffered
saline) without adding the peptide. Rats in the C16-treated group
(n = 16) each received 0.5 mL of C16 solution, while the vehicle
(control) group was treated with 0.5 mL of the same solvent with-
out adding the peptide via IV injection of the tail vein. The ﬁrst
dose was given immediately after EAE induction (see above), and
the IV injection repeating every day for 2 weeks in the tail veins
was achieved by starting injections at the caudal end of the base
of the tail and into one vein. Injection sites were moved to the
alternate left or right sides and increasingly rostral on subsequent
days.
PERFUSION AND TISSUE PROCESSING
Animals from each group were sacriﬁced after 2 or 8 weeks (ﬁve
rats per time point in each group) post-immunization. Rats
were anesthetized with intraperitoneal injections of 1% Nem-
butal (40 mg/kg) and perfused intracardially with cold saline
followed by 4% paraformaldehyde in 0.1 M phosphate buffer
(PB, pH 7.4). After undergoing ex vivo magnetic resonance imag-
ing (MRI) scans, the spinal cord and brain tissues were carefully
dissected. One centimeter of the lumbar spinal cord and a half
of the brain of each animal were ﬁxed in the same ﬁxative
for 4 h and then transferred into 30% sucrose in PBS until
the tissue sunk to the bottom of the container. Twenty micro-
thick sections were cut on a freezing microtome through the
coronal plane of the brain and transverse plane of the spinal
cord using a Leica cryostat and then mounted onto 0.02%
poly-L-lysine-coated slides. All sectionswere collected for histolog-
ical assessment and immunohistological and immunoﬂuorescent
staining. The remains of the CNS tissue were ﬁxed in 2.5%
glutaraldehyde solution and examined by transmission electron
microscope.
MAGNETIC RESONANCE IMAGING
Ex vivo MRI scanning of ﬁxed brains was performed using a
clinical 3.0 T MRI machine (Signa HDxt 3 T) equipped with a
dedicated solenoid rat coil. Rats were placed in the cradle supine
position. T2-weighted sequences (15 contiguous coronal slices of
1.5 mm each) were collected with the following characteristics:
TE = 120 ms, TR = 3200 ms, slice thickness = 1.5 mm, number
of slices = 15, 320 × 192 matrix, ﬁeld of view = 60 mm × 60 mm,
ﬂip angle = 90◦.
HISTOLOGY ASSESSMENT
Hematoxylin and eosin (H&E) staining and cresyl violet (Nissl)
staining were employed to assess inﬂammation and neuron
survival, respectively. Neuron counts from both spinal cord
anterior horns were performed and restricted to the neurons
with a well-deﬁned nucleolus and a cell body with adequate
amounts of endoplasmic reticulum. Digital images were col-
lected using a Nikon TE-300 microscope in three visual ﬁelds/per
section with 200× magniﬁcation under bright ﬁeld viewing.
Besides, Bielschowsky silver staining was performed as previously
described to estimate axonal loss (Fang et al., 2013) and MBP
immunohistochemical labeling was used to evaluate the degree of
demyelination.
QUANTITATIVE MEASUREMENTS
Images of were taken on an Nikon brightﬁeld and ﬂuorescence
microscope and images digitized with an attached Spot camera
(MI, USA). All images within a type of staining were taken with
the same exposure time. Quantiﬁcation of myelinated area was
performed by calculation of MBP-positive pixels in one series of
sections (200 μm apart) by the threshold feature of Scion Image
software (Scion Corporation, Frederick, MD, USA). Brieﬂy, after
the transformation of each section to a binary image, the percent-
age of black pixels was calculated for every section, and the average
of three consecutive images was calculated. Since single inﬂam-
matory cells were too difﬁcult to discern at the injury site, the
inﬁltrationof inﬂammatory cellswas digitizedusing a 5×objective
and the area occupied by these extravasated cells were calculated
for the three sections (ﬁve ﬁelds in each). To provide a measure of
the number of preserved axons, the number of Bielschowsky silver
stained axons intersecting 100-mm spaced horizontal (ﬁve) and
vertical (six) lines were counted in each image through a series of
sections (each 200 μm apart; Han et al., 2010; Muradov and Hagg,
2013) under 200× magniﬁcation.
IMMUNOHISTOCHEMICAL STAINING
Slides were warmed for 20 min on a slide warmer, and a ring of
wax was applied around the sections with a PAP pen (Invitro-
gen, Carlsbad, CA, USA). After rinsing in 0.01 M Tris-buffered
saline (TBS) for 10 min, the sections were permeabilized and
blocked with 0.3% Triton X-100/10% normal goat serum in
0.01 M PBS for 30 min, then incubated with the following poly-
clonal rabbit antibodies: anti-CD4 (1:500, AbCam, Cambridge,
MA, USA), anti-CD45 (1:200; AbCam), CD68/ED1 (1:200; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), anti-tumor necrosis
factor alpha (TNF-α; 1:1000; ProSci Incorporated, CA,USA), anti-
caspase 3 (1:500; Cayman Chemical, Ann Arbor, MI, USA), and
anti-160KD neuroﬁlament M (NF-M; 1:1000; Neuromics, MN,
USA), as well as mouse anti-myelin basic protein (MBP; 1:500;
AbCam) overnight at 4◦C. The process of immunohistochemical
staining was performed as described previously (Fang et al., 2013).
Primary antibody omission controls were used in order to conﬁrm
further the speciﬁcity of the immunohistochemical labeling. Five
sections from the motor cortex and anterior horns of the spinal
cord of each animal were randomly selected, and images were
photographed under 200× magniﬁcation in three visual ﬁelds per
section.
Frontiers in Neuroanatomy www.frontiersin.org December 2013 | Volume 7 | Article 44 | 3
“fnana-07-00044” — 2013/12/26 — 15:00 — page 4 — #4
Fang et al. Effects of C16 peptide and CNTF in acute EAE
IMMUNOFLUORESCENCE STAINING
Sections were pretreated with the same method described above,
incubated with polyclonal rabbit anti-glia ﬁbrillary acidic pro-
tein (GFAP; 1:200; Thermo Fisher Scientiﬁc, Waltham, MA, USA)
overnight at 4◦C, then washed with PBS and incubated with
FITC-conjugated goat anti-rabbit IgG secondary antibodies (1:200
dilution) for 1 h at 37◦C (Invitrogen). The sections were mounted
with antifade Gel/Mount aqueous mounting media (Southern-
Biotech, AL, USA). All control sections were incubated in PBS
without primary antibodies.
PROCESSING FOR ELECTRON MICROSCOPY
Tissues ﬁxed with 2.5% glutaraldehyde were washed three times
with 0.1 M PB, post-ﬁxed in 1% osmium tetroxide at 4◦C
overnight, and then washed three times with 0.1 M PB. The
processing for electron microscopy was performed as described
previously (Fang et al., 2013). Images were captured ﬁrst at low
resolution and then at higher magniﬁcation in different regions of
the white matter.
CYTOKINE QUANTIFICATION BY ENZYME-LINKED IMMUNOSORBENT
ASSAY
Peripheral blood samples were collected from rats that were sacri-
ﬁced by decapitation at weeks 2 and 8 post-immunization (n = 3
per time point for each group). Plasma samples were collected on
ice following centrifuge for 20 min at 1000 × g within 30 min
of collection and centrifugation at 10,000 × g for 10 min at 4◦C
for complete platelet removal, using heparin as an anticoagulant.
All samples were aliquot and stored at -80◦C. To assess cytokine
expression, plasma samples were incubated in 96-well plates pre-
coated with antibodies to IFN-γ (BioLegend Inc., San Diego, CA,
USA) and TGF-β (R&D Systems, Minneapolis, MN,USA) at 37◦C
for 60 min. Horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG (Bio-Rad, Hercules, CA,USA) diluted 1:2,000 was used
as a secondary antibody. The optical density was measured at
450 nm on a Model 680 Microplate Reader (Bio-Rad) and was
quantiﬁed using GraphPad Prism 4 software (GraphPad Software,
Inc, CA, USA).
WESTERN BLOTTING
Rats were sacriﬁced by decapitation at weeks 2 and 8 post-
immunization (n = 3 rats per time point in each group), and
whole brain tissues and a 10-mm lumbar spinal cord segment
were prepared for Western blotting from each animal. Total
proteins were extracted from the intact spinal cord 1 mL EDTA-
free ice-cold RIPA buffer with 2 mM PMSF and added protease
inhibitor cocktail. Protein concentrations were determined using
the Bradford protein assay. SDS-PAGE was performed on 15%
polyacrylamide slab gels, and separated proteins were then elec-
trophoretically transferred to PVDF membranes at 70 V for 1.5 h
at 4◦C in a Bio-Rad TransBlot apparatus. After blocking non-
speciﬁc binding sites with bovine serum albumin, each membrane
was incubated for 12 h at room temperature with primary rabbit
polyclonal anti-GFAP (1:500), anti-NF-M (1:2000), anti-TNF-α
(1:2000), or anti-caspase 3 (1:500) antibodies. The process of
Western blot was performed as previous described (Fang et al.,
2011). To normalize protein bands to a gel loading control,
membranes were washed in TBST and re-probed with rabbit
anti-β-actin antibodies (1:5,000, AbCam) followed by incubation
with HRP-conjugated goat anti-rabbit antibodies (1:5,000) and
ECL detection. For the negative control, the primary antibody was
omitted.
STATISTICAL ANALYSIS
Kruskal–Wallis non-parametric analysis was used for data pre-
sented as percentages. Differences between clinical scores and
histological scores were analyzed with Mann–Whitney tests. All
data were analyzed in SPSS 13.0 software, and P-values less than
0.05 were considered statistically signiﬁcant. All statistical graphs
were created in GraphPad Prism Version 4.0.
RESULTS
EFFECTS OF TREATMENT WITH CNTF AND/OR C16 ON PERIVASCULAR/
PARENCHYMAL INFLAMMATION IN THE EAE RAT MODEL
For determination of the types of inﬂammatory cells inﬁltrating
these tissues, we performed immunostaining for the detection
of CD4, a marker for extravasated T lymphocytes; CD45, a
pan-leukocyte marker for leukocytes; and CD68, a marker for
activated microglia and extravasated macrophages (Figure 1).
Numerous CD4+, CD45+, and CD68+ inﬂammatory cells inﬁl-
trated the CNS of vehicle-treated EAE rats (Figures 1A,E,I),
while markedly reduced perivascular and parenchymal inﬁl-
trations of these inﬂammatory cells were detected in CNTF−
(Figures 1B,F,J), C16− (Figures 1C,G,K), and CNTF+C16-
treated (Figures 1D,H,L) EAE rats.
At the peak time of the disease (2 weeks after immunization),
the cerebral cortex and spinal cord of EAE rats treated with vehicle
all revealed a signiﬁcant increase in cellular inﬁltration. Diffuse
inﬁltration of inﬂammatory cells appeared not only surrounding
blood vessels and under the meninges, but also widely inﬁltrating
the parenchyma of the brain tissue. At week 8 post-immunization,
the extent of inﬁltration and the size of perivascular inﬁltration
foci decreased compared with those at week 2 post-immunization
in the vehicle control. Treatment with either C16 or C16 plus
CNTF markedly suppressed the inﬁltration of inﬂammatory cells
in different cell types, but CNTF treatment did not result in obvi-
ous reduction of inﬂammation at week 8 post-immunization. The
combined treatment (C16 plus CNTF) caused a more obvious
impairment of the inﬂammatory reaction at week 2 but not at
week 8 post-immunization (Figures 1M,N).
Magnetic resonance imaging T2W scanning revealed clear
lesion foci with hyperintensity in the brain tissues of vehicle-
treated EAE rats at week 2 post-immunization (white area with
high density in Figure 2A) and visible lesion still could be found
at week 8 post-immunization (density increase area showed by
arrow in hippocampi and cortex of vehicle-treated EAE rats in
Figure 2E) although it smaller than lesion site at week 2 post-
immunization. An intensity increased lesion area was detected
in CNTF treated group (Figure 2F), but not in C16 treated
(Figure 2G) and C16 plus CNTF treated (Figure 2H) EAE rats at
week 8 post-immunization. However, there were no visible lesion
foci in C16-, CNTF-, and C16 plus CNTF-treated groups at weeks
2 post-immunization (Figures 2B–D).
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FIGURE 1 | At week 2 post-immunization, infiltration of inflammatory
cells was observed surrounding blood vessels in the cortex and spinal
cord of vehicle-treated EAE rats, and this effect was attenuated by
treatment with C16 and CNTF. (A–D) CD4 immunostaining; (E–H),
CD45 immunostaining; (I–L), CD68 immunostaining, counterstained with
hematoxylin, bar = 100 μm. (M,N) CNTF and C16 treatment inhibited
inﬂammatory cell inﬁltration at week 2 (M) and week 8 (N) post-
immunization. *P < 0.01 versus the vehicle-treated EAE rats; #P < 0.01
versus CNTF-treated EAE rats; &P < 0.01 versus C16-treated EAE
rats.
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FIGURE 2 |The MRIT2W scanning showed clear hyperintensity lesion
site appear in brain cortex of vehicle treated EAE rats but not in CNTF
and C16 treated EAE rats. (A) Vehicle treated EAE rats at week 2
post-immunization, arrow illustrating a clear hyperintensity area in the white
matter. There were no visible lesion foci in (B) CNTF treated EAE rats,
(C) C16 treated EAE rats, and (D) C16+CNTF treated EAE rats at week 2
post-immunization. (E) Vehicle treated EAE rats at week 8
post-immunization. Arrow showed hyperintensity lesion area still existed,
although a little smaller than lesion site at week 2 post-immunization. An
intensity increased lesion area was detected in CNTF treated group [arrow in
(F)], but not in C16 treated (G) and C16+CNTF treated (H) EAE rats at week
8 post-immunization.
EFFECTS OF TREATMENT WITH CNTF AND/OR C16 ON DEMYELINATION
AND AXON LOSS
Using MBP (one of the major central myelin proteins) immuno-
histochemical staining, we checked the total demyelination con-
dition of rats in each group. Large plaques of demyelination were
detected in the CNS of vehicle-treated EAE rats at the peak time
of the disease (week 2 post-immunization, Figure 3B), when
compared with the normal rats (Figure 3A). At week 8 post-
immunization, the demyelination condition when compared with
the normal rats (Figures 6A,B) in the vehicle control was reduced.
As expected, the demyelination was dramatically reduced by C16
or CNTF treatment (Figures 3C–E), and was reduced even more
by combined treatment with C16 plus CNTF when compared
with vehicle treatment at both weeks 2 and 8 post-immunization
(Figures 3F,G).
Bielschowsky staining revealed that the injured axons exhib-
ited swelling, deformation, and ovoid formation (Figure 4C).
Vehicle-treated EAE rats displayed severe axonal loss in both
the white and gray matter of the CNS at week 2 post-
immunization (Figures 4C,D) when compared with the normal
rats (Figures 4A,B). However, both the C16 and CNTF treat-
ments protected the injured axons and keep them into relatively
normal shape (Figures 4E–L). In the meantime, immunoﬂuo-
rescence labeling of NF-M, a cytoskeletal intermediate ﬁlament
protein found speciﬁcally in neurons, demonstrated that the lum-
bar spinal cord neurons were undergoing swelling and disruption,
with the dendrites and axons atrophy, shortening, and exhibiting
fragmentation, accompanied by the inﬁltration of inﬂammatory
cells (Figures 5B,F). Compared with the vehicle control, more
axons with relatively normal formation were maintained in C16-,
CNTF-, and C16 plus CNTF-treated EAE rats at each time point
(Figures 5B–G). Much higher NF-M expression and less severe
depletion of motor neurons were also found in C16-, CNTF-, and
C16 plus CNTF-treated rats, as compared with the vehicle con-
trol at the same time point (Figures 5F,G) had showed a typical
comparison of injured and protected neurons). Simultaneously,
Western blot analysis revealed an obvious decrease in neuroﬁl-
ament M expression in the vehicle control, and this effect was
signiﬁcantly reversed by treatment with C16, CNTF, or C16 plus
CNTF at both weeks 2 and 8 post-immunization (Figure 5).
Transmission electron microscopy examination further
revealed that a considerable amount of themyelin sheath displayed
splitting and vacuolated changes in the vehicle control group
(Figure 6C) when compared with the normal rats (Figures 6A,B).
Shrunken axons were covered by disrupted myelin sheaths, and,
in some places, the axons even disappeared (Figure 6C). Severe
edema and leakage of inﬂammatory cells from the blood vessels
were detected in the extracellular space surrounding the vessels
(Figures 6D,E). The neurons of the vehicle control showed signs of
apoptosis, including shrunkennucleiwith condensed, fragmented,
and marginated nuclear chromatin (Figure 6F). In contrast,
C16-, CNTF-, and C16 plus CNTF-treated groups exhibited more
lightly vacuolated myelin sheaths, with the corresponding axons
and neighboring nuclei resembling the normal ultrastructure
(Figures 6G–J). At week 8 post-immunization, demylination,
and remyelination appeared simultaneously in vehicle-treated
EAE rats (Figure 6K). Meanwhile, more remyelinated ﬁbers
appeared in C16-, CNTF-, and C16 plus CNFT-treated groups
(Figure 6L).
EFFECTS OF TREATMENT WITH CNTF AND/OR C16 ON APOPTOSIS AND
NEURON LOSS IN THE CNS OF EAE RATS
There was marked neuron loss in the anterior horn of spinal cords
and motor cortices of the vehicle-treated EAE rats at both weeks
2 and 8 post-immunization (Figures 7C,D) when compared with
normal animals (Figures 7A,B). However, in C16-, CNTF-, and
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FIGURE 3 |Treatment with CNTF or C16 reduced demyelination in the
spinal cord and cerebral cortex, as revealed by MBP immunostaining,
counterstained with hematoxylin (coronal sections of brain motor
cortex), Bar = 100 μm. At week 2 post-immunization, normal control group
(A), vehicle-treated EAE rats (B), CNTF-treated EAE rats (C), C16-treated EAE
rats (D), and C16+CNTF-treated rats (E). (F,G)Treatment with CNTF or C16
prevented demyelination at week 2 (F) and week 8 (G) post-immunization.
aP < 0.05 versus the normal control; bP < 0.05 versus vehicle-treated EAE
rats; cP < 0.05 versus CNTF-treated EAE rats; d P < 0.05 versus C16-treated
EAE rats.
C16 plus CNTF-treated EAE rats, more neurons were present in
the CNS (Figures 7E–L).
Western blot analysis also showed the expression of apoptotic
signal molecule caspase-3 (an enzyme involved in the execution of
the mammalian apoptotic cell death program) evidently increased
in the vehicle control, and this effect was signiﬁcantly reversed by
treatment with C16, CNTF, or C16 plus CNTF at both weeks 2
and 8 post-immunization (Figure 8). The change in the number
of caspase-3 immunoreactive neuronal cells in each group was
consistent with the expression levels detected by Western blotting
(Figures 8A–H).
EFFECTS OF TREATMENT WITH CNTF AND/OR C16 ON REACTIVE
ASTROCYTE PROLIFERATION AND REACTIVE GLIOSIS IN EAE RATS
To assess the effects of treatment with CNTF and C16 on EAE-
induced reactive gliosis, we examined the expression of GFAP, a
marker for astrocytes, by Western blot analysis and immunoﬂuo-
rescence labeling. Immunolabeling showed that astrocytes prolif-
erated and formed a visible glial scar (Figures 9C,D). Westerns
blot revealed that the expression of GFAP increased in both
the spinal cord and cerebral cortex of vehicle-treated EAE rats
(Figures 9I–N). Additionally, GFAP expression and astrocyte
proliferation were signiﬁcantly reduced in both C16− and CNTF-
treated group at week 2 post-immunization (Figure 9), and the
combined treatment with C16 plus CNTF resulted in an even
better suppressing effect on glial scar formation (Figure 9). How-
ever, at week 8 post-immunization, the C16− and C16 plus
CNTF-treated groups exhibited amoremarked inhibitionof astro-
cytes proliferation than the CNTF-treated group (Figures 9G–H).
GFAP expression in the CNTF-treated group was obviously
increased and approached the observed GFAP expression of the
vehicle control at this time point (Figure 9F).
EFFECTS OF TREATMENT WITH CNTF AND C16 ON THE EXPRESSION OF
THE PRO-INFLAMMATORY CYTOKINES TNF-α AND IFN-γ AND THE
ANTI-INFLAMMATORY CYTOKINE TGF-β
The results of Western blot analysis showed that at early (week 2)
and late (week 8) stages of the clinical course, the motor cortex
and spinal cord of vehicle control-treated EAE rats contained high
levels of TNF-α expression (Figure 10). Also, a marked decrease
in TNF-α expression in C16-, CNTF-, and C16 plus CNTF-treated
groups, from weeks 2 to 8 post-immunization was conﬁrmed by
Western blotting (Figure 10).
Next, the expression of IFN-γ and TGF-β in blood serum
was measured by enzyme-linked immunosorbent assay (ELISA).
Results showed that the expression of TGF-β in C16-, CNTF-,
and C16 plus CNTF-treated groups all increased when compared
with that in the normal control, but did not show signiﬁcant
improvement when compared with that in vehicle-treated EAE
rats (Figures 11A,B). Nevertheless, treatment with C16, CNTF, or
C16 plus CNTF all noticeably reduced the expression of IFN-γ,
which was obviously increased in the blood serum of vehicle
control-treated EAE rats (Figures 11C,D).
EFFECTS OF TREATMENT WITH CNTF AND C16 ON DISEASE
PROGRESSION AND SEVERITY
In vehicle-treated rats, disease symptoms appeared on day 7–9
post immunization. The acute phase of the disease began with
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FIGURE 4 |Treatment with CNTF or C16 alleviated axonal loss in the
spinal cord and cerebral cortex, as revealed by Bielschowsky
staining, [(A,C,E,G,I): coronal sections of brain motor cortex;
(B,D,F,H,J): traverse sections through anterior horn of lumbar spinal
cord], bar = 100 μm. At week 2 post-immunization, (A,B) normal
control group, (C,D) vehicle-treated EAE rats [(C) axons were undergoing
gradual loss and exhibiting deformed and ovoid formation, the neurons
have lost dendrite and axons when compared with the normal neurons
in (A,B)], (E,F) CNTF-treated EAE rats, (G,H) C16-treated EAE rats, and
(I,J) C16+CNTF-treated rats. More axons were shown in these groups.
(K,L) Treatment with CNTF or C16 prevented axon loss. aP < 0.05
versus the normal control; bP < 0.05 versus vehicle-treated EAE rats;
cP < 0.05 versus CNTF-treated EAE rats; d P < 0.05 versus C16-treated
EAE rats.
a sharp increase in motor symptoms, which peaked at week 2
post-immunization (Figures 11E–G). Thereafter, the clinical score
gradually declined. At week 8 post-immunization, the clinical
score of surviving vehicle-treated animals returned to a level of
1–2 (Figures 11E–G). In general, animals treated with C16, CNTF,
or C16 plus CNTF showed a similar disease course as the vehicle
group, with a delayed onset (when the clinic score exceeded 2, on
day 9–12 post-immunization), an obviously reduced clinical score
in peak stage and a more rapid recovery. All of these effects were
especially notable in the combined C16 plus CNTF-treated group
(Figures 11E–G).
DISCUSSION
Multiple sclerosis is characterized by inﬂammation, demyeli-
nation, axonal injury, and neuronal loss (Noseworthy et al.,
2000; Hellings et al., 2002; El Behi et al., 2005). Hallmarks of
active MS include perivascular inﬁltrates of microglia-derived
macrophages, activated T lymphocytes, and reactive changes of
astrocytes (Makar et al., 2008). Tissue damage and demyelination
are caused by macrophages and T lymphocytes, which secrete pro-
inﬂammatory cytokines, such as interleukin-1 (IL-1), IFN-γ, and
TNF-α (Zindler and Zipp, 2010; Hou et al., 2012; Yin et al., 2012).
This extensive neuroinﬂammation results in ongoing demyelina-
tion and axonal/neuronal injury mirrored by progressive physical
disability (Tsutsui et al., 2004). Several immunomodulatory agents
that inhibit this neuroinﬂammation have been shown to inﬂuence
the course of MS (Kerschensteiner et al., 2004; Stanislaus et al.,
2004). Thus, regulating inﬂammatory mediators and reducing
innate immune activation is a rational therapeutic strategy for
the treatment of MS.
Experimental autoimmune encephalomyelitis is still the most
widely accepted animal model of MS. Different types of EAE
have been developed in order to investigate pathogenetic, clin-
ical, and therapeutic aspects of the heterogenic human disease.
Generally, investigations in EAE are more suitable for the analysis
of histopathological features (inﬂammation, demyelination, and
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FIGURE 5 |Treatment with CNTF or C16 alleviated neuronal atrophy
and axonal disruption at week 2 post-immunization. (A–G) NF-M
immunostaining, counterstained with hematoxylin, traverse sections through
anterior horn of lumbar spinal cord, bar = 100 μm. (A) Normal control group.
(B) Inﬂammatory inﬁltrates, neuronal atrophy, and dendrite and axonal
disruption in vehicle-treated EAE rats. (C–E) Lots of perikaryal and axonal
hyper-NF-M immunostaining motor neurons appeared in CNTF-treated (C),
C16-treated (D), and C16+CNTF-treated (E) EAE rats. (F,G)The enlarged
image of vehicle-treated (F) and C16+CNTF-treated (G) EAE rats. The motor
neurons at the anterior horn of spinal cord lost the normal shape and cell
skeleton which labeled by NF-M (F), when compared with the normal shape
motor neurons with NF-M labeled kytoplasm and neuritis (G). NF-M
expression decreased markedly in both the spinal cord (H,J) and cerebral
cortex (I,K) following EAE induction, but up-regulated after treatment with
CNTF or C16, as compared with the vehicle treated control, at weeks 2 and 8
post-immunization, as shown byWestern blotting. (L,M) NF-M expression
in the spinal cord and brain cortex at week 2 (L) and week 8 (M) post-
immunization revealed by western blotting. aP < 0.05 versus normal control;
bP < 0.05 versus vehicle-treated EAE rats; d P < 0.05 versus CNTF-treated
EAE rats.
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FIGURE 6 | Electron micrographs demonstrating the prevention of
myelination or axon loss and inhibition of neuronal apoptosis by CNTF
and C16 treatment. (A,B) Normal control group [(A), normal myelinated
axons exhibited dark ring-shaped myelin sheaths surrounding the axon;
(B), normal nuclei of neuron with uncondensed chromatin]. (C–F) Vehicle-
treated EAE rats at week 2 post-immunization. The myelin sheath displayed
splitting, vacuoles (showed by arrow), and loose and fused changes, and
axons were shrunken and dissolving (C). Severe leaking out of the blood
vessels and tissue emeda were detected in the extracellular space
surrounding the vessels [showed by arrow in (D)]. (E) Inﬁltrated leukocytes
(showed by arrow) near the vascular endothelial cell (showed by red
arrowhead). (F)The neurons of the vehicle control showed apoptotic signs of
shrunken nuclei with condensed, fragmented, and marginated nuclear
chromatin. The CNTF− (G), C16− (H), and C16+CNTF-treated (I) groups
exhibited more lightly vacuolated myelin sheaths. The neighboring nuclei (J)
of C16+CNTF-treated rats resembled the normal ultrastructure. At week 8
post-immunization in the vehicle control group, demylination (arrow) and
remyelination (arrowhead) simultaneously appeared in vehicle-treated EAE
rats (K). Meanwhile, more remyelinated ﬁbers appeared in C16+CNTF-treated
(L) groups.
degeneration) of the disease than for screening of new treatments.
For example, even aggressive immunosuppression is not sufﬁcient
to treat progressive MS. All EAE models are directly accessible to
investigation of the immune and nervous system, which interact
during the pathogenesis of the disease and which are both tar-
geted by established and experimental therapies. Despite extensive
screening for new targets of MS therapy in EAE so far, only a few
of the established MS therapies have been developed in the animal
model (examples are glatiramer acetate, mitoxantrone, and natal-
izumab), all these therapies were set to target the pathogenesis of
the disease process just like our agents (Mix et al., 2010).
In the current study, we showed that treatment with CNTF
and/or C16 attenuated perivascular/parenchymal inﬂammation
and decreased the size of lesions which was associated with the
persistent inﬂammatory inﬁltration and perivascular edema. The
inhibition of αυβ3 integrins has been shown to reduce leukocyte-
endothelial interactions in a reperfusion model (Ichioka et al.,
2007). The C16 peptide can recognize and bind to αυβ3, which
plays an important role in leukocyte accumulation and adhe-
sion processes (Weerasinghe et al., 1998; Ponce et al., 1999; Han
et al., 2010), and competitively block transmigration of leuko-
cytes attempting to cross the endothelium. In agreement with this
hypothesis on themechanism of C16 peptide, our previous studies
demonstrated that the widespread perivascular and parenchy-
mal inﬁltration of leukocytes, lymphocytes, and extravasated
macrophages in the CNS of EAE rats were all signiﬁcantly
Frontiers in Neuroanatomy www.frontiersin.org December 2013 | Volume 7 | Article 44 | 10
“fnana-07-00044” — 2013/12/26 — 15:00 — page 11 — #11
Fang et al. Effects of C16 peptide and CNTF in acute EAE
FIGURE 7 |Treatment with CNTF or C16 reduced the loss of neurons
both in the spinal cord and brain. Nissl staining, bar = 100 μm.
[(A,C,E,G,I): coronal sections of brain motor cortex; (B,D,F,H,J): traverse
sections through anterior horn of lumbar spinal cord]. At week 8
post-immunization, normal animals (A,B), vehicle-treated EAE rats (C,D),
CNTF-treated EAE rats (E,F), C16-treated EAE rats (G,H), and C16
+CNTF-treated EAE rats (I,J). (K,L) The CNTF-, C16-, and C16+CNTF-
treated EAE rats all gained more neurons in the motor cortex, and
anterior horn of the spinal cord. Neuron counts were restricted to the
neurons with a well-deﬁned nucleolus and a cell body with adequate
amounts of endoplasmic reticulum, in three visual ﬁelds/per section
with 200× magniﬁcation under bright ﬁeld viewing. Surviving neural
cells (each group % of the normal control) in different groups at week
2 (K) and week 8 (L) post-immunization, calculated after Nissl staining.
aP < 0.05 versus the normal control; bP < 0.05 versus vehicle-treated
EAE rats.
suppressed by consecutive IV injection of C16 (Fang et al., 2013).
Inﬂammation scores were also clearly decreased compared with
that of the vehicle control. Moreover, in addition to taking part
in the inﬁltration process of inﬂammatory cells, αυβ3 integrin is
thought to be an important receptor that regulates macrophage
differentiation and macrophage responses to external signaling
and maintains chronic inﬂammatory processes in pathological
conditions (Antonov et al., 2011). Thus, besides interfering with
the leukocyte transmigration, C16 application may also directly
inhibit macrophage-related inﬂammation via blockage of αυβ3.
While we gave daily injections for 2 weeks, half of the animals sur-
vived for 8 weeks. Thus, these sustained neuroprotective effects
observed at the later stage of the EAE model (week 8 post-
immunization) suggested that neurotrophic treatments may have
lasting effects, even when treatment has been halted.
Previous studies of CNTF have demonstrated that it impairs
inﬂammation in mouse models of MS (Stankoff et al., 2002;
Kuhlmann et al., 2006). Moreover, in the acute phase of EAE,
treatment with CNTF does not change the peripheral immune
response, but did reduce the number of perivascular inﬁltrates
of T cells and the levels of diffuse microglial activation in the
spinal cord (Kuhlmann et al., 2006). In addition, blood brain
barrier (BBB) permeability is signiﬁcantly reduced in CNTF-
treated animals (Kuhlmann et al., 2006). It is speculated that the
clinical beneﬁts of CNTF in EAE are caused mainly by prevent-
ing inﬂammatory cell recruitment to the CNS via effects on the
BBB (Kuhlmann et al., 2006), and this mechanism overlaps, at
least in part, with the proposed mechanism of C16. Our results
showed that at the early stage of disease progression (week 2 fol-
lowing immunization), CNTF treatment markedly suppressed the
inﬁltration of inﬂammatory cells, in accordance with the above-
mentioned speculation on CNTF. However, at later stages (week 8
following immunization), CNTF administration did not cause an
obvious reduction in inﬂammation, this phenomenon was con-
sistent with the non-lasting anti-inﬂammatory effects of CNTF,
which has been previously reported by Kuhlmann et al. (2006).
Widespread demyelination and axonal loss are the pathologi-
cal hallmarks of MS (Pluchino et al., 2003). Microglial activation
and migration is essential for the development of demyelina-
tion (Pluchino et al., 2003). The loss of myelin-derived trophic
support caused axonal damage and the primary inﬂammatory
attack on axonal targets, which is also associated with acute motor
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FIGURE 8 | Treatment with CNTF or C16 reduced the number of
apoptotic neural cells in the brain cortex and spinal cord.
(A–H) Caspase-3 immunostaining, counterstained with hematoxylin,
bar = 100 μm. [(A,C,E,G): coronal sections of brain motor cortex;
(B,D,F,H): traverse sections through anterior horn of lumbar spinal cord].
At week 2 post-immunization, vehicle-treated EAE rats (A): many
caspase-3 labeled apoptotic neural cells appeared in the hindlimb area
of the motor cortex; (B) plenty of caspase-3 labeled apoptotic neural
cells appeared in the anterior horn of the spinal cord). In CNTF− (C,D),
C16− (E,F), and C16+CNTF-treated (G,H) rats, the density of caspase-3
expression in neuronal cells was decreased, and the number of
caspase-3+ apoptotic neural cells was also obviously reduced.
Caspase-3 expression declined markedly both in the spinal cord (I,K)
and cerebral cortex (J,L) following treatment with CNTF or C16 at
weeks 2 and 8 post-immunization, as shown by western blotting. (M,N)
Caspase-3 expression in the spinal cord and brain cortex at week 2 (M)
and week 8 (N) post-immunization revealed by western blotting.
aP < 0.05 versus the normal control; bP < 0.05 versus vehicle-treated
EAE rats; cP < 0.05 versus C16-treated EAE rats; d P < 0.05 versus
CNTF-treated EAE rats.
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FIGURE 9 |Treatment with CNTF or C16 inhibited reactive gliosis, as
revealed by FITC-conjugated GFAP immunofluorescent staining (traverse
sections through the lumbar spinal cord), bar = 100 μm. At week 2
post-immunization; (A) normal control group, (B) enlarged image showed the
normal astrocytes. (C,D) Vehicle-treated EAE rats, showing astrocyte
proliferation and formation of a visible glial scar (in (C)]. At week 8
post-immunization, vehicle-treated EAE rats (E) and CNTF-treated EAE rats
(F) all exhibited evident glial scar formation, while reactive gliosis markedly
decreased in C16− (G) and C16+CNTF-treated (H) EAE rats. (I-L) GFAP
expression was visibly reduced at week 2 post-immunization following CNTF,
C16, and C16+CNTF treatment, but not at week 8 post-immunization
following CNTF treatment, as shown byWestern blotting. (M,N): aP < 0.05
versus normal control; bP < 0.05 versus vehicle-treated EAE rats; cP < 0.05
versus C16-treated EAE rats; d P < 0.05 versus CNTF-treated EAE rats.
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FIGURE 10 |TNF-α expression decreased markedly in both the spinal
cord (A,C) and cerebral cortex (B,D) following treatment with CNTF or
C16, as compared with the vehicle control, at weeks 2 and 8
post-immunization, as shown byWestern blotting. (E,F)TNF-α expression
in the spinal cord and brain cortex at week 2 (E) and week 8 (F)
postimmunization revealed byWestern blotting. aP < 0.05 versus normal
control; bP < 0.05 versus vehicle-treated EAE rats; cP < 0.05 versus
C16-treated EAE rats; d P < 0.05 versus CNTF-treated EAE rats.
axon neuropathy (Bjartmar et al., 1999; Bannerman et al., 2005;
Huizinga et al., 2008). The inﬂammation, demyelination, and
axonal fragmentation in the CNS and PNS lead to motor neu-
ron injury, which further leads to atrophy and neuronal death
(Huizinga et al., 2008; Dutta and Trapp, 2011). Motor neuronal
abnormalities contribute to spinal cord atrophy, limb weakness,
and physical disability (Bjartmar et al., 1999; Huizinga et al., 2008;
Dutta and Trapp, 2011). Additionally, neurological recovery in
acute EAE rats has also been shown to be associated with the
restoration of nerve conduction in the CNS and PNS via remyeli-
nation of demyelinated ﬁbers by oligodendrocytes or Schwann
cells (Pender, 1989). Besides demyelination, survival and dif-
ferentiation of neurons also contributes to disease progression.
The role of CNTF as a survival and differentiation factor for
neurons and oligodendrocytes is well established (Clatterbuck
et al., 1993; Linker et al., 2002). Previous studies have shown
that CNTF promotes the survival of neurons and reduces serum
deprivation-induced cell death of oligodendrocytes (Kuhlmann
et al., 2006). In myelin oligodendrocyte glycoprotein-induced
EAE, the disease was more severe and the vacuolar dystrophy
of myelin, axonal damage, and neuronal loss were also more
serious in CNTF-deﬁcient mice than in wild-type mice (Linker
et al., 2002). Moreover, CNTF acts on oligodendrocytes by favor-
ing their ﬁnal maturation and promoting remyelination in MS
(Stankoff et al., 2002). All of these studies implied the direct neu-
roprotective effects of CNTF in the inﬂammatory environment
and are consistent with our results of CNTF treatment, which
showed that CNTF administration could alleviate demyelination,
prevent axon loss, and reduce neuronal death. Even at a later
stage, when inﬂammation returned after cessation of CNTF treat-
ment, many more intact myelin, axons, and neurons could still be
detected.
In acute EAE models, inﬁltrated leukocytes and activated
macrophages/microglia may produce a pro-inﬂammatory milieu,
strip off myelin from axons, and induce apoptosis in neurons
and oligodendrocytes that are highly vulnerable to an aggravated
microenvironment (Crowe et al., 1997; Liu et al., 1997; Warden
et al., 2001). Therefore, targeting the neuroinﬂammatory reaction
has been critical in the protection of motor neurons and the alle-
viation of clinical motor symptoms. In our study, C16 treatment
resulted in a decrease in demyelination and relief of axonal dam-
age at both weeks 2 and 8 post-immunization. The less abnormal
ultrastructure and the more remyelinated axons observed under
electron microscopy further conﬁrmed the positive effects of C16
treatment on myelin and axons. All these phenomena may be
ascribed to the amelioration of the inﬂammatory milieu. The
improved microenvironment could further reduce the death of
neurons and oligodendrocytes, which would be beneﬁcial for the
remyelination of demyelinated ﬁbers.
Reactivated astroglia, which accumulated within and at the
margins of demyelinating lesions, were GFAP-positive cells that
were substantially larger than normal stellate astroglia. These cells
are derived from adult radial glias that undergo mitosis and phe-
notypic transformation soon after the onset of CNS inﬂammation
(Bannerman et al., 2007). The phenomenon of astrogliosis is due
to both astroglial hyperplasia and hypertrophy in regions proximal
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FIGURE 11 | (A–D) Treatment with CNTF and C16 reduced the
expression of the pro-inﬂammatory cytokines IFN-γ but no evident
effects on the expression of anti-inﬂammatory cytokine TGF-β. (A,B)
TGF-b levels in plasma samples from different groups at weeks 2 (A)
and 8 (B) post-immunization, as measured by ELISA. (C,D) IFN-γ levels
in plasma samples from different groups at weeks 2 (A) and 8 (D)
post-immunization, as measured by ELISA. aP < 0.05 versus the normal
control; bP < 0.05 versus vehicle-treated EAE rats; cP < 0.05 versus
CNTF-treated EAE rats. (E–G) Treatment with CNTF or C16 halted
disease progression and reduced disease severity. The clinical
progression of EAE was attenuated after CNTF (E), C16 (F), and
C16+CNTF (G) treatments. aP < 0.05 versus the vehicle-treated group
at the same time point. aaP < 0.01 versus the vehicle-treated group at
the same time point.
to inﬂammatory inﬁltrates (Bannerman et al., 2007). Previous
studies have shown that the migration of oligodendroglial lin-
eage cells into lesions was retarded by intense perilesional gliosis
(Bannerman et al., 2007). Reactive astroglia also contributed
to the inﬂammatory response in MS and EAE by synthesizing
pro-inﬂammatory cytokines and chemokines and by present-
ing peptide antigens to T lymphocytes (Balasingam et al., 1994).
Diminishing reactive astrogliosis in and around EAE and MS
lesions could diminish oligodendroglial death, enhance oligoden-
droglial regeneration, and facilitate remyelination (Bannerman
et al., 2007). Our results indicated that C16 and CNTF treatment
could reduce the proliferation of reactive astrocytes and decrease
reactive gliosis, which may contribute to their beneﬁcial effects
at impairing inﬂammation. With the improved regional microen-
vironment and decreased demyelination, C16 treatment caused
an obvious suppression of reactive astrocyte proliferation. The
effects of CNTF on reactive astrogliosis were similar to those of
C16 at week 2 post-immunization, which was consistent with its
anti-inﬂammatory effects when the drug was delivery persistently.
Nevertheless, after cessation of CNTF treatment, GFAP+-reactive
astroglia andGFAP expressionwere increased in theCNTF-treated
group, which was possibly related to the return of the inﬂamma-
tory response and the facilitative effects of CNTF on the survival
of glial cells.
Microglia, macrophages, and astrocytes have been implicated
in the pathogenesis of MS by secreting a number of molecules,
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such as the pro-inﬂammatory cytokines TNF-α, IL-6, and IFN-γ,
which act as inﬂammatory mediators and/or tissue damaging
agents Stanislaus et al., 2002) CD4+ T helper 1 (Th1) lympho-
cytes can also produce TNF-α and IFN-γ, which could further
induce a local inﬂux of inﬂammatory cells and worsen EAE dis-
ease progression (Garay et al., 2007). The administration of CNTF
and C16 can block perivascular inﬁltrates of inﬂammatory cells,
alleviate microglial/macrophage activation, and inhibit reactive
astrocyte proliferation; thus, pro-inﬂammatory factors produced
by these cells would decrease accordingly. Moreover, previous
studies have suggested that CNTF may counterbalance this effect
of TNF-α, which further inferred the downstream signal trans-
duction pathway and reduced the secondary transmigration of
inﬂammatory cells (Linker et al., 2002); this may explain how the
combined treatment further decreased the levels of TNF-α and
IFN-γ.
On the other hand, the expression of TGF-β, an anti-
inﬂammatory cytokine produced by CD4+ T helper 2 (Th2) cells,
increased slightly over that of the normal control in vehicle-,
CNTF-, C16-, and C16+CNTF-treated EAE rats (Zhang et al.,
2006). This phenomenon may be a compensation reaction in
the inﬂammatory microenvironment. However, the expression
of TGF-β in C16-, CNTF-, and combined C16+CNTF-treated
groups showed no signiﬁcant improvement when compared with
vehicle-treated EAE rats, which may be due to similar suppressing
effects on Th1 and Th2 cells.
Previous and recent results demonstrated that C16 could
inhibit the extensive inﬁltration of leukocytes and activation of
macrophages by competitively blocking the integrins interfering
with the leukocyte transmigration. Moreover, by improving the
microenvironment, it may alleviate disease severity at the peak
time of EAE progression and lead to a more rapid recovery of
locomotor function. In addition to impaired inﬂammation, CNTF
also exerted direct neuroprotective effects, alleviating demyelina-
tion, preventing axon loss, and reducing neuronal death, which
contributed to the delay of disease onset and the decline of max-
imum clinical scores. Compared with individually treatment, the
combined treatment with C16 and CNTF produced more dra-
matic effects on the inﬂammation inhibition, neuroprotection,
and functional recovery. These results suggested that, even though
they have partly overlapping underlying mechanisms, CNTF and
C16 still could exert their neuro-protective actions and gain better
synergistic effects through targeting different pathways.
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